Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Lease Agreements (Tables)

3 Months Ended

Mar. 31, 2019

For the three months ended March 31, 2019, the components of our operating lease expense were as follows (in thousands):


Fixed operating lease expense	$	1,256
Variable operating lease expense		249
Total operating lease expense	$	1,505

Supplemental information related to the Company’s operating lease for the three months ended March 31, 2019 was as follows (in thousands):


Cash payments included in the measurement of operating lease liabilities	$	2,308
Right-of-use asset obtained in exchange for operating lease obligations		—

The following table presents the maturity of our operating lease liabilities as of March 31, 2019 (in thousands):


Remainder of 2019	$	7,014
2020		9,694
2021		10,082
2022		10,485
2023		877
Total operating lease payments		38,152
Less: imputed interest		(6,447)
Total operating lease liabilities	$	31,705

For the three months ended March 31, 2019, we have the following operating sublease information (in thousands):

The following table presents the future lease payments expected to be received under our sublease as of March 31, 2019 (in thousands):


Remainder of 2019	$	3,154
2020		4,360
2021		4,534
2022		4,716
2023		394
Total operating lease liabilities	$	17,158